Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma

BACKGROUND: Patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) or R/R systemic anaplastic large-cell lymphoma (sALCL) treated with brentuximab vedotin (BV) experienced high remission rates in two Phase II trials. With increased response rates and survival times, patient-reported outcomes...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Onco Targets Ther
Autori principali: Chen, Robert, Allibone, Suzanne, Bartlett, Nancy L, Brice, Pauline, Chen, Andy, Pose, Katrina, Rich, Lynn, Bonthapally, Vijay, Garfin, Phillip M, Fanale, Michelle
Natura: Artigo
Lingua:Inglês
Pubblicazione: Dove Medical Press 2016
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4827881/
https://ncbi.nlm.nih.gov/pubmed/27103829
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S96175
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi